Karyotypic and fluorescent in-situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms 8. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:392-7. 9. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 2007;39(2):59-70. 10. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007: 453-9. 11. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418-29. 12. Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009;94(4):454-9. Comment on: Haematologica. 2009;94(4): 542-9. 13. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndromes: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379-87. 14. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108(8):2509-19. 15. McCarthy CJ, Sheldon S, Ross CW, McCune WJ. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum. 1998;41(8):1493-6. 16. Young NS. Pathophysiologic mechanisms in acquired aplastic anemia. Hematology Am Soc Hematol Educ Program. 2006: 72-7. 17. Maciejewski JP, Selleri C. Evolution of clonal cytogenetics abnormalities in aplastic anemia. Leuk Lymphoma. 2004;45(3): 433-40. 18. Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program. 2004:318-36. 19. Yunis JJ, Sawyer JR, Ball DW. The characterization of high- resolution G-banded chromosomes of man. Chromosoma. 1978; 67(4):293-307. 20. Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, Rao KW, Rao PN; Association for Molecular Pathology Clinical xxx Practice Committee; American College of Medical Genetics Laboratory Quality Assurance Committee. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007;9(2):134-43. 21. Shaffer LG, Slovak ML, Campbel LJ, editors. ISCN: an International System for Chromosome Nomenclature. Basel: Karger; 2009. 22. Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood. 1991;78 (11):2982-8. 23. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10): 4841-51. 24. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389-98. 25. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88. Comment in: Blood. 2001;98(6):1985; Blood. 1997;90(7): 2843-6. 26. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factor and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23 (30):7594-603. 27. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76(6):1083-91. 28. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetics, and prognostic features. J Clin Oncol. 1986;4(12):1748-57. 29. Takeyama K, Seto M, Uike N, Hamajima N, Ino T, Mikuni C, et al Therapy-related leukemia and myelodysplastic syndrome: a large- scale japanese study of clinical and cytogenetic features as well as prognostic factors. Inter J Hematol. 2000;71(2):144-52. 30. Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi-Deliliers G. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia. 1993;7(6):838-47. Rev Bras Hematol Hemoter. 2011;33(6):425-31 431